https://link.springer.com/article/10.1007/s12035-020-02070-6
Specific Considerations for Neuroinvasion in COVID-19 With the probable SARS-CoV2 neuroinvasion, it is worth considering the specific treatment options in addition to the current COVID-19 management protocol. Apart from the antiviral strategy, there were animal studies on the possibility of modulating CNS excitatory pathways, i.e., the glutamate homeostasis [58,59,60]. A known N-methyl-D-aspartate (NDMA) receptor antagonist, memantine, improved the symptoms, reduced motor disabilities, and the viral replication in coronavirus-infected mice [58]. Other NMDA receptor blockers, including dizocilpine, agmatine sulfate, and ifenprodil, also reduced the neuronal death, the intraocular pressure (IOP), the reactive gliosis, and the neurodegeneration in the ZIKA-infected mice [59]. A glutamine antagonist, 6-diazo-5-oxo-l-norleucine, reduced CNS leukocyte migration, prevented inflammation, paralysis, and death in mice [60]. With the worsening prognosis of SARS-CoV2 neuroinvasion, these options are probably reserved for compassionate considerations.